The negotiated prices of 15 Medicare Part D drugs, which include several blockbusters, will go into effect in 2027.

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Novo sells semaglutide as Ozempic and Rybelsus for diabetes and as Wegovy for obesity. In price talks, CMS will treat the different forms as a single product.

The U.S. Centers for Medicare and Medicaid Services released its list of drugs covered under Medicare Part D selected for the ...

The U.S. government targets Novo Nordisk's drugs, including Ozempic and Wegovy, for Medicare price negotiations in 2027.

In other news, Novo Nordisk announced the results from its phase 3b STEP UP semaglutide trial today. Specifically, the ...

The US plans to slash the price it pays for the Novo Nordisk A/S blockbusters Ozempic and Wegovy, the latest drugs to be ...

Stock prices for Novo Nordisk dropped precipitously Friday after a last-minute announcement from the Biden administration ...

The US plans to slash the price it pays for the Novo Nordisk A/S blockbusters Ozempic and Wegovy, the latest drugs to be ...

Medicare has announced 15 new drugs up for price negotiations, set to begin in the next several months with top drugmakers, ...

Novo Nordisk said that patients taking a higher dose of its blockbuster Wegovy obesity shot lost more weight than those on a lower dose without experiencing an increase in side-effects, according to a ...

Novo Nordisk said on Friday a late-stage trial with a high-dose version of its weight loss drug semaglutide helped overweight ...